6484-27-1

Basic information

• Product Name: 4-CHLORO-2-PYRIDIN-4-YLQUINAZOLINE
• Synonyms: 4-CHLORO-2-PYRIDIN-4-YLQUINAZOLINE
• CAS NO: 6484-27-1
• Molecular Formula: C₁₃H₈ClN₃
• Molecular Weight: 241.68
• Mol File: 6484-27-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-CHLORO-2-PYRIDIN-4-YLQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2-PYRIDIN-4-YLQUINAZOLINE(6484-27-1)
• EPA Substance Registry System: 4-CHLORO-2-PYRIDIN-4-YLQUINAZOLINE(6484-27-1)

Safety Data

• Hazardous Substances Data: 6484-27-1(Hazardous Substances Data)

Upstream product

• 88-65-3 2-bromobenzoic-acid 
• 872-85-5 pyridine-4-carbaldehyde 
• 118-92-3 anthranilic acid 
• 57696-11-4 2-(pyridine-4-yl)-4H-benzo[d][1,3]oxazine-4-one 
• 6484-23-7 C₁₃H₉N₃O 
• 419557-85-0 N-(2-Carbamoyl-phenyl)-isonicotinamide 
• 28144-70-9 anthranilic acid amide 
• 14254-57-0 4-(chlorocarbonyl)pyridine 
• 6484-23-7 2-(pyridin-4'-yl)quinazolin-4-(3H)-one 

Downstream Products

• 157863-22-4 3-((2-(pyridin-4-yl)quinazolin-4-yl)amino)benzoic acid 

Relevant articles and documents

Copper mediated one-pot synthesis of quinazolinones and exploration of piperazine linked quinazoline derivatives as anti-mycobacterial agents

A facile method was developed for the synthesis of quinazolinone derivatives in a one-pot condensation reaction via in situ amine generation using ammonia as the amine source and with the formation of four new C-N bonds in good to excellent yields. With the optimised method, we synthesized a library of piperazine linked quinazoline derivatives and the synthesized compounds were evaluated for their inhibitory activity against Mycobacterium tuberculosis. The compounds 8b, 8e, 8f, 8m, 8n and 8v showed potent anti-mycobacterial activity with MIC values of 2-16 μg mL-1. All the synthesized compounds follow Lipinski's rules for drug likeness. This journal is

Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance

P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a principal obstacle for successful cancer chemotherapy. A novel P-gp inhibitor with a quinazoline scaffold, 12k, was considered to be the most promising for in-depth study. 12k possessed high potency (EC50 = 57.9 ± 3.5 nM), low cytotoxicity, and long duration of activity in reversing doxorubicin (DOX) resistance in K562/A02 cells. 12k also boosted the potency of other MDR-related cytotoxic agents with different structures, increased accumulation of DOX, blocked P-gp-mediated Rh123 efflux, and suppressed P-gp ATPase activity in K562/A02 MDR cells. However, 12k did not have any effects on CYP3A4 activity or P-gp expression. In particular, 12k had a good half-life and oral bioavailability and displayed no influence on DOX metabolism to obviate the side effects closely related to increased plasma concentrations of cytotoxic agents in vivo.

HETEROCYCLIC AND BICYCLIC COMPOUNDS, COMPOSITIONS AND METHODS

The present invention provides, among other things, new bicyclo heterocyclic compounds, compositions comprising these heterocyclic compounds, methods of making the heterocyclic compounds, and methods of using these heterocyclic compounds for treating a variety of conditions and disease states associated with, for example, cellular proliferation, inflammation, glycosidase expression, or the low expression of Perlecan.